vs
越洋钻探（RIG）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
越洋钻探的季度营收约是Revvity的1.4倍（$1.0B vs $772.1M），Revvity净利率更高（12.7% vs 2.4%，领先10.3%），越洋钻探同比增速更快（9.6% vs 5.9%），越洋钻探自由现金流更多（$321.0M vs $161.8M），过去两年越洋钻探的营收复合增速更高（16.9% vs 9.0%）
越洋钻探（Transocean Ltd.）是按营收计全球规模最大的海上钻探承包商，总部位于瑞士施泰因豪森，起源于美国，目前在加拿大、美国、挪威、英国、印度、巴西、新加坡等20个国家设有办事机构，业务覆盖全球主要海上油气开采区域。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
RIG vs RVTY — 直观对比
营收规模更大
RIG
是对方的1.4倍
$772.1M
营收增速更快
RIG
高出3.7%
5.9%
净利率更高
RVTY
高出10.3%
2.4%
自由现金流更多
RIG
多$159.2M
$161.8M
两年增速更快
RIG
近两年复合增速
9.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.0B | $772.1M |
| 净利润 | $25.0M | $98.4M |
| 毛利率 | 42.0% | — |
| 营业利润率 | 23.0% | 14.5% |
| 净利率 | 2.4% | 12.7% |
| 营收同比 | 9.6% | 5.9% |
| 净利润同比 | 257.1% | 3.9% |
| 每股收益（稀释后） | $0.13 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收RIGRVTY
| Q4 25 | $1.0B | $772.1M | ||
| Q3 25 | $1.0B | $698.9M | ||
| Q2 25 | $988.0M | $720.3M | ||
| Q1 25 | $906.0M | $664.8M | ||
| Q4 24 | $952.0M | $729.4M | ||
| Q3 24 | $948.0M | $684.0M | ||
| Q2 24 | $861.0M | $691.7M | ||
| Q1 24 | $763.0M | $649.9M |
净利润RIGRVTY
| Q4 25 | $25.0M | $98.4M | ||
| Q3 25 | $-1.9B | $46.7M | ||
| Q2 25 | $-938.0M | $53.9M | ||
| Q1 25 | $-79.0M | $42.2M | ||
| Q4 24 | $7.0M | $94.6M | ||
| Q3 24 | $-494.0M | $94.4M | ||
| Q2 24 | $-123.0M | $55.4M | ||
| Q1 24 | $98.0M | $26.0M |
毛利率RIGRVTY
| Q4 25 | 42.0% | — | ||
| Q3 25 | 43.2% | 53.6% | ||
| Q2 25 | 39.4% | 54.5% | ||
| Q1 25 | 31.8% | 56.5% | ||
| Q4 24 | 39.2% | — | ||
| Q3 24 | 40.6% | 56.3% | ||
| Q2 24 | 38.0% | 55.7% | ||
| Q1 24 | 31.5% | 54.6% |
营业利润率RIGRVTY
| Q4 25 | 23.0% | 14.5% | ||
| Q3 25 | -163.1% | 11.7% | ||
| Q2 25 | -97.6% | 12.6% | ||
| Q1 25 | 7.1% | 10.9% | ||
| Q4 24 | 13.7% | 16.3% | ||
| Q3 24 | -51.2% | 14.3% | ||
| Q2 24 | -6.9% | 12.4% | ||
| Q1 24 | -0.4% | 6.8% |
净利率RIGRVTY
| Q4 25 | 2.4% | 12.7% | ||
| Q3 25 | -187.1% | 6.7% | ||
| Q2 25 | -94.9% | 7.5% | ||
| Q1 25 | -8.7% | 6.4% | ||
| Q4 24 | 0.7% | 13.0% | ||
| Q3 24 | -52.1% | 13.8% | ||
| Q2 24 | -14.3% | 8.0% | ||
| Q1 24 | 12.8% | 4.0% |
每股收益（稀释后）RIGRVTY
| Q4 25 | $0.13 | $0.86 | ||
| Q3 25 | $-2.00 | $0.40 | ||
| Q2 25 | $-1.06 | $0.46 | ||
| Q1 25 | $-0.11 | $0.35 | ||
| Q4 24 | $-0.14 | $0.77 | ||
| Q3 24 | $-0.58 | $0.77 | ||
| Q2 24 | $-0.15 | $0.45 | ||
| Q1 24 | $0.11 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $620.0M | $919.9M |
| 总债务越低越好 | $5.2B | — |
| 股东权益账面价值 | $8.1B | $7.3B |
| 总资产 | $15.6B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.64× | — |
8季度趋势，按日历期对齐
现金及短期投资RIGRVTY
| Q4 25 | $620.0M | $919.9M | ||
| Q3 25 | $833.0M | $931.4M | ||
| Q2 25 | $377.0M | $991.8M | ||
| Q1 25 | $263.0M | $1.1B | ||
| Q4 24 | $560.0M | $1.2B | ||
| Q3 24 | $435.0M | $1.2B | ||
| Q2 24 | $475.0M | $2.0B | ||
| Q1 24 | $446.0M | $1.7B |
总债务RIGRVTY
| Q4 25 | $5.2B | — | ||
| Q3 25 | $4.8B | — | ||
| Q2 25 | $5.9B | — | ||
| Q1 25 | $5.9B | — | ||
| Q4 24 | $6.2B | — | ||
| Q3 24 | $6.5B | — | ||
| Q2 24 | $6.8B | — | ||
| Q1 24 | $6.8B | — |
股东权益RIGRVTY
| Q4 25 | $8.1B | $7.3B | ||
| Q3 25 | $8.1B | $7.4B | ||
| Q2 25 | $9.4B | $7.6B | ||
| Q1 25 | $10.2B | $7.6B | ||
| Q4 24 | $10.3B | $7.7B | ||
| Q3 24 | $10.2B | $7.9B | ||
| Q2 24 | $10.7B | $7.9B | ||
| Q1 24 | $10.5B | $7.8B |
总资产RIGRVTY
| Q4 25 | $15.6B | $12.2B | ||
| Q3 25 | $16.2B | $12.1B | ||
| Q2 25 | $17.8B | $12.4B | ||
| Q1 25 | $19.0B | $12.4B | ||
| Q4 24 | $19.4B | $12.4B | ||
| Q3 24 | $19.5B | $12.8B | ||
| Q2 24 | $20.3B | $13.4B | ||
| Q1 24 | $19.9B | $13.4B |
负债/权益比RIGRVTY
| Q4 25 | 0.64× | — | ||
| Q3 25 | 0.60× | — | ||
| Q2 25 | 0.63× | — | ||
| Q1 25 | 0.58× | — | ||
| Q4 24 | 0.60× | — | ||
| Q3 24 | 0.64× | — | ||
| Q2 24 | 0.63× | — | ||
| Q1 24 | 0.65× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $349.0M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $321.0M | $161.8M |
| 自由现金流率自由现金流/营收 | 30.8% | 21.0% |
| 资本支出强度资本支出/营收 | 2.7% | 2.6% |
| 现金转化率经营现金流/净利润 | 13.96× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $626.0M | $509.4M |
8季度趋势，按日历期对齐
经营现金流RIGRVTY
| Q4 25 | $349.0M | $182.0M | ||
| Q3 25 | $246.0M | $138.5M | ||
| Q2 25 | $128.0M | $134.3M | ||
| Q1 25 | $26.0M | $128.2M | ||
| Q4 24 | $206.0M | $174.2M | ||
| Q3 24 | $194.0M | $147.9M | ||
| Q2 24 | $133.0M | $158.6M | ||
| Q1 24 | $-86.0M | $147.6M |
自由现金流RIGRVTY
| Q4 25 | $321.0M | $161.8M | ||
| Q3 25 | $235.0M | $120.0M | ||
| Q2 25 | $104.0M | $115.5M | ||
| Q1 25 | $-34.0M | $112.2M | ||
| Q4 24 | $177.0M | $149.8M | ||
| Q3 24 | $136.0M | $125.6M | ||
| Q2 24 | $49.0M | $136.6M | ||
| Q1 24 | $-169.0M | $129.7M |
自由现金流率RIGRVTY
| Q4 25 | 30.8% | 21.0% | ||
| Q3 25 | 22.9% | 17.2% | ||
| Q2 25 | 10.5% | 16.0% | ||
| Q1 25 | -3.8% | 16.9% | ||
| Q4 24 | 18.6% | 20.5% | ||
| Q3 24 | 14.3% | 18.4% | ||
| Q2 24 | 5.7% | 19.7% | ||
| Q1 24 | -22.1% | 20.0% |
资本支出强度RIGRVTY
| Q4 25 | 2.7% | 2.6% | ||
| Q3 25 | 1.1% | 2.6% | ||
| Q2 25 | 2.4% | 2.6% | ||
| Q1 25 | 6.6% | 2.4% | ||
| Q4 24 | 3.0% | 3.4% | ||
| Q3 24 | 6.1% | 3.3% | ||
| Q2 24 | 9.8% | 3.2% | ||
| Q1 24 | 10.9% | 2.7% |
现金转化率RIGRVTY
| Q4 25 | 13.96× | 1.85× | ||
| Q3 25 | — | 2.97× | ||
| Q2 25 | — | 2.49× | ||
| Q1 25 | — | 3.03× | ||
| Q4 24 | 29.43× | 1.84× | ||
| Q3 24 | — | 1.57× | ||
| Q2 24 | — | 2.87× | ||
| Q1 24 | -0.88× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
RIG
| Ultra Deepwater Floaters | $433.0M | 42% |
| BR | $236.0M | 23% |
| Other Geographical | $211.0M | 20% |
| Harsh Environment Floaters | $163.0M | 16% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
